DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

Journal of Medical Primatology

Volumn 31, Issue 1, 2002, Pages 40-60

  Rasmussen, Robert A ^a,b   Hofmann Lehmann, R ^a,b   Montefiori, D C ^c   Li, P L ^a,b   Liska, V ^a,b   Vlasak, J ^a   Baba, T W ^a,b,d   Schmitz, J E ^b,e   Kuroda, M J ^b,e   Robinson, H L ^f   McClure, H M ^f   Lu, S ^g   Hu, S L ^h   Rizvi, T A ⁱ   Ruprecht, R M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytolytic T lymphocytes; gp160; Neutralizing antibodies

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; PRIMER DNA; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA; VIRUS VACCINE; VPU PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CHRONOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE COUNT; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROVOCATION TEST; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS INTERFERENCE; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANIMALS, NEWBORN; CD4 LYMPHOCYTE COUNT; CHIMERA; DNA, VIRAL; HIV; IMMUNIZATION, SECONDARY; MACACA MULATTA; PLASMIDS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

ANIMALIA; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036099015     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0684.2002.1o019.x     Document Type: Article

References (62)

1. Flow microfluorometric analysis of peripheral blood mononuclear cells from nonhuman primates: Correlation of phenotype with immune function
2. Watkins DI: Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
3. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
4. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
5. Human neutralizing monoclonal anti-bodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
6. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
7. Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1
8. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees
9. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
10. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys
11. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
12. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
13. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids
14. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
15. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
16. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12
17. In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose
18. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
19. DNA vaccines
20. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene- gun inoculations
21. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: Boost are mediated by nitric oxide
22. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multi-epitope gene and DNA prime- modified vaccinia virus Ankara boost vaccination regimen
23. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: Comparison of one- versus two-enzyme systems
24. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
25. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys
26. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
27. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants
28. Cross-neutralizing anti-bodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus
29. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
30. Analysis of gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
31. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: The role of nitric oxide
32. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
33. Viremia and AIDS in rhesus macaques after intramuscular inoculation of plasmid DNA encoding full-length SIVmac239
34. Vaccination of mice and nonhuman primates using HIV-gene-containing DNA
35. Developing DNA vaccines against immunodeficiency viruses
36. Simian immunodeficiency virus DNA vaccine trial in macaques
37. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice
38. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
39. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
40. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys
41. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors
42. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
43. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
44. Gene gun-based nucleic acid immunization. Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA
45. Th1 genetic adjuvants modulate immune responses in neonates
46. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques
47. Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease
48. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
49. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
50. Rev/RRE-independent Mason-Pfizer monkey virus constitutive transport element-dependent propagation of SIV-mac239 vectors using a single round of replication assay
51. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
52. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
53. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
54. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
55. Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus
56. The ontogeny of antigen-specific T cells
57. Gene vaccination: Plasmid DNA is more than just a blueprint
58. Interleukin-12: Basic principles and clinical applications
59. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells
60. Gene inoculation generates immune responses against human immunodeficiency virus type 1
61. Administration of recombinant human interleukin 12 to chronically SIVmac-infected rhesus monkeys
62. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine